Skip to content
Screener

Insulet PODD Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$00.0%
Embecta Corp. logo
Embecta Corp.EMBC
$0.010.0%
Omada Health logo
Omada HealthOMDA
$00.0%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$00.0%
Medtronic logo
MedtronicMDT
InfuSystem Holdings logo
InfuSystem HoldingsINFU

Other financials

Income statement

See full
Revenue$801.7M+23.5%
Gross profit$562.6M+24.4%
Operating income$129.7M+7.1%
Net income$95.0M+322%
EPS (diluted)$1.37+328%

Balance sheet

See full
Cash & equivalents$534.9M-52.3%
Total debt$974.7M-47.6%
Total equity$1.4B-2.8%
Total assets$3.2B-8.8%

Cash flow

See full
Operating cash flow$88.4M-55.0%
CapEx$32.5M+74.7%
Free cash flow$55.9M-68.6%

Valuation

See full
Market cap$9.79B-53.8%
Enterprise value$10.23B-53.4%
P/E26.1×-63.7×
P/S3.2×-5.8×

Profitability

See full
Gross margin71.1%+0.3pp
Operating margin16.9%-0.4pp
Net margin12.3%+2.3pp
FCF margin9.6%-7.5pp

Returns & leverage

See full
Return on equity26%+6.8pp
Debt / equity0.7×-0.6×
Current ratio2.5×+0.2×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: Insulet’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001145197-26-000169
(in millions, except share and per share data)June 30, 2026December 31, 2025
Commitments and contingencies (note 11)
Stockholders’ Equity
Preferred stock, $0.001 par value, 5,000,000 authorized; none issued and outstanding
Common stock, $0.001 par value,100,000,000 authorized; 70,798,932 and 70,588,192 issued0.10.1
Additional paid-in capital1,309.01,274.9
Accumulated earnings473.5287.4
Accumulated other comprehensive income1.912.5
Treasury stock, at cost; 1,447,918 and 197,374 shares(363.5)(60.4)

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Insulet's common stock, par value (in dollars per share)?
Insulet (PODD) reported common stock, par value (in dollars per share) of $0 in Q2 2026.
How has Insulet's common stock, par value (in dollars per share) changed year-over-year?
Insulet's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
What is the long-term trend for Insulet's common stock, par value (in dollars per share)?
Over 5 years (2020 to 2025), Insulet's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.
What does common stock, par value (in dollars per share) mean?
Common stock, par value (in dollars per share)

Ask your AI about Insulet's common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude